Lucas Patel

Lucas Patel

Auto-generated profile, based on publicly available information

Lucas Patel

Bioinformatics and Systems Biology Program, University of California San Diego, La Jolla, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2020 in Molecular Cell
Verified
Journal Article
Closed access
RLRebecca K. Lau
Rebecca K. Lau
QYQiaozhen Ye
Qiaozhen Ye
EBErica A. Birkholz
Erica A. Birkholz
KBKyle R. Berg
Kyle R. Berg
LPLucas Patel
Lucas Patel
KCKevin D. Corbett
Kevin D. Corbett

18 February 2019 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
PDF file
LPLucas Patel
Lucas Patel
RKRhea Kang
Rhea Kang
SRScott C. Rosenberg
Scott C. Rosenberg
YQYunjiang Qiu
Yunjiang Qiu
RRRamya Raviram
Ramya Raviram
KCKevin D. Corbett
Kevin D. Corbett

6 July 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
PMParaskevi Massara
Paraskevi Massara
JKJonathan Kirkland
Jonathan Kirkland
IPIoanna Pagani
Ioanna Pagani
Samantha Lee HueySamantha Lee Huey
Samantha Lee Huey
HHHaym Hirsh
Haym Hirsh
Saurabh MehtaSaurabh Mehta
Saurabh Mehta
A key feature of the Precision Nutrition and Health approach is the ability to tailor interventions to individual variability using multimodal data from large-scale biobanks and cohorts. Artificial intelligence (AI) and machine learning (ML) models offer new potential to model complex data but remain constrained by challenges related to data quality, interpretability, validation, and causal inference. This Perspective synthesizes current AI/ML methodologies in PN, elucidates their interplay with the distinctive features of multi-omic and nutritional data, such as being compositional, episodic, context-dependent, and error-prone, and delineates nutrition-specific best practices for achieving robust, interpretable, and clinically actionable AI integration in research and practice.

7 July 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
RLRebecca K. Lau
Rebecca K. Lau
QYQiaozhen Ye
Qiaozhen Ye
LPLucas Patel
Lucas Patel
KBKyle R. Berg
Kyle R. Berg
IMIan T. Mathews
Ian T. Mathews
KCKevin D. Corbett
Kevin D. Corbett
Bacteria possess an array of defenses against foreign invaders, including diverse nucleases that target and destroy the genome of an invading bacteriophage or foreign DNA element. A recently-described bacteriophage immunity pathway employs a cGAS/DncV-like nucleotidyltransferase to produce a cyclic tri-AMP second messenger, which activates the DNA endonuclease effector NucC. Here, we show that NucC is related to restriction enzymes but uniquely assembles into a homotrimer in solution. cAAA binding in a conserved allosteric pocket promotes assembly of two NucC trimers into a homohexamer competent for double-strand DNA cleavage. We propose that NucC mediates bacteriophage immunity either through global activation, causing altruistic cell death and abortive infection, or through local activation and targeted phage genome destruction. Finally, we identify NucC homologs in type III CRISPR-Cas systems, where they likely function as accessory nucleases activated by cyclic oligoadenylate second messengers synthesized by these systems’ effector complexes.

4 March 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
VCVincent Charron-Lamoureux
Vincent Charron-Lamoureux
PKPatricia Kelly
Patricia Kelly
SZSimone Zuffa
Simone Zuffa
APAbubaker Patan
Abubaker Patan
MSMarta Sala-Climent
Marta Sala-Climent
PDPieter C. Dorrestein
Pieter C. Dorrestein
Microbially modified bile acids shape host physiology by regulating nutrient absorption, glucose homeostasis, circadian rhythms and thermoregulation. Here we identify a previously unrecognized drug-activating function of microbial bile acid conjugation. By systematically mining human LC–MS/MS datasets across public repositories and linking uncharacterized bile acid spectra to health-associated metadata, we discovered conjugates of the >75-year-old anti-inflammatory drug 5-aminosalicylic acid (5-ASA) with primary and secondary bile acids, including cholic, deoxycholic and lithocholic acids. These bile acid–drug conjugates were detected specifically in individuals treated with 5-ASA or its prodrugs. Multiple gut bacteria, including members of the Bacteroidota and Bacillota, generated cholyl–5-ASA in vitro, and bile salt hydrolase–associated transaminase activity was required for conjugate formation. In a mouse model of colitis, cholyl–5-ASA was associated with reduced intestinal inflammatory pathology and showed markedly enhanced activation of PPAR-γ in cell-based reporter assays compared with 5-ASA alone. Consistent with this activity, cholyl–5-ASA elicited selective immunophenotypic changes in CD4⁺ T cells in vitro, including increased Foxp3+ regulatory T cells. Together with prior evidence that 5-ASA efficacy depends on the microbiome, these findings support a model in which microbial bile acid conjugation represents a key activation step for 5-ASA therapy. More broadly, this work demonstrates how pan-repository metabolomics can uncover previously unrecognized microbiome-dependent chemical functions with direct therapeutic relevance.

28 September 2026 in Gut Microbes
Verified
Journal Article
Open access
THTim Hensen
Tim Hensen
LKLora Khatib
Lora Khatib
LPLucas Patel
Lucas Patel
DMDaniel McDonald
Daniel McDonald
AGAntonio González
Antonio González
ITInes Thiele
Ines Thiele
1. Alzheimer’s disease (AD) is the most common neurodegenerative disease. AD is generally characterized by a progressive loss of neurons, extracellular accumulation of amyloid beta proteins, and in...